Search
Acarbose
go.drugbank.com/drugs/DB00284ApprovedInvestigationalAcarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. … Acarbose is therefore used in conjunction with diet, exercise, and other pharmacotherapies for the management of blood sugar levels in patients with type 2 diabetes.
Categories: Drugs Used in DiabetesCilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigational[L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022. … Cilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigational[L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022. … Tixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for
Rezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigational[L45633,L45658] It was subsequently approved in the EU in November of the same year. [L52745] … Rezafungin is an echinocandin antifungal drug.
Trofinetide
go.drugbank.com/drugs/DB06045Approved[A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union. … Trofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor
Mitomycin
go.drugbank.com/drugs/DB00305ApprovedInvestigational[A193419] Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper … Tract Urothelial Cancer (LG-UTUC)[L12867] - as well as adjunctly to _ab externo_ glaucoma surgeries.
Categories: Compounds used in a research, industrial, or household settingOlutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigational[L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. … [L44256] IDH1 mutations are common in different types of cancer, such as gliomas, AML, intrahepatic cholangiocarcinoma, chondrosarcoma, and myelodysplastic syndromes (MDS), and they lead to an increase
Azficel-T
go.drugbank.com/drugs/DB11051ApprovedWithdrawnAzficel-T is marketed in the US as Laviv for intradermal injection. … As a replacement for lost dermal constituents in the aging or skin deformation process, treatment with autologous fibroblasts has shown to improve wrinkle and acne scar appearance than with placebo treatment
Amsilarotene
go.drugbank.com/drugs/DB21085InvestigationalAmsilarotene is under investigation in clinical trial NCT00687596 (Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy … Amsilarotene has a monoisotopic molecular weight of 385.15 Da.
Polatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigational[L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141] … humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB